INM InMed Pharmaceuticals Inc.

BEARISH Impact: 7/10 EFFECT
Horizon days Filed Mar 31, 2026 Processed 2mo ago SEC 9999999995-26-000999
IPO/offering going effective
Latest settled — T+20d
INM ▲ +8.68% at T+20d
SHORT call ✗ call lost -8.68% · α vs SPY +0.74% · entry $0.6450 → $0.7010
Next anchor: T+60d in 16d
Last close $1.54 (close Jun 8) · -138.76% from $0.6450 entry (call sign-flipped)
Entry anchored
Mar 30, 02:12 PM ET
via Databento tick
T+1d
+3.88%
call -3.88% · α -3.13%
$0.6700
settled 2mo ago
T+5d
+0.31%
call -0.31% · α +3.63%
$0.6470
settled 2mo ago
T+20d
+8.68%
call -8.68% · α +0.74%
$0.7010
settled 6w ago
T+60d
call — · α —
in 16d

Price Chart

Loading chart...

Executive Summary

InMed Pharmaceuticals' S-3 shelf registration has become effective, allowing the company to raise up to $50 million through future offerings of common shares, preferred shares, warrants, or other securities. Given the company's $2 million market cap and existing going concern doubts, this creates a significant dilution overhang.

Actionable Insight

Monitor for imminent takedown of shares under this shelf; any offering will be highly dilutive given current market cap. Downward pressure on share price is likely upon announcement of any issuance.

Key Facts

  • S-3 shelf registration became effective on March 30, 2026
  • Company may raise up to $50 million in aggregate value over time
  • Offering can include common stock, preferred stock, warrants, subscription rights, or units
  • Market cap is only $2 million, implying potential for extreme dilution
  • Company faces substantial doubt about going concern due to operating losses and adverse U.S. legislation impacting BayMedica

Financial Impact

Up to $50 million in potential dilution against a $2 million market cap

dilutionequity valueshare price

Risk Factors

  • Extreme shareholder dilution due to large shelf size relative to market cap
  • Equity issuances could further depress share price in a low-liquidity environment
  • Ongoing going concern risks exacerbated by reliance on capital markets for survival

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-000999
Document: 9999999995-26-000999-index.html9999999995-26-000999
Document: 9999999995-26-000999.txt9999999995-26-000999
8 reports for INM
Performance horizon
60% Hit rate 3 of 5 directional calls best @ T+5▲ +19.19%Mar 20, 2026
Filters
Rows
Reports for INM — sortable, filterable
Type Now
May 19, 2026
21d ago
425
MIXED ★ 7/10
$1.60 $1.69▲ +5.63%▲ +3.38%$1.54 (−3.75%)
May 19, 2026
21d ago
8-K
BULLISH ★ 8/10
$1.60 $1.69▲ +5.63%▲ +3.38%$1.54 (−3.75%)
May 19, 2026
21d ago
8-K
BEARISH ★ 7/10
$1.60 $1.66▼ −3.75%▼ −1.45%$1.54 (+3.75%)
Apr 27, 2026
6w ago
8-K
BEARISH ★ 8/10
$0.7010 $0.7480▼ −6.70%▼ −5.01%$1.54 (−119.69%)
Apr 3, 2026
9w ago
8-K
NEUTRAL ★ 3/10
$0.6950 $0.7130▲ +2.59%▼ −1.54%$1.54 (+121.58%)
Apr 3, 2026
9w ago
424B5
BEARISH ★ 8/10
$0.6950 $0.7130▼ −2.59%▲ +1.54%$1.54 (−121.58%)
Mar 31, 2026
10w ago
EFFECT
BEARISH ★ 7/10
$0.6450 $0.6470▼ −0.31%▲ +3.63%$1.54 (−138.76%)
Mar 20, 2026
11w ago
S-3
BEARISH ★ 7/10
$0.7610 $0.6150▲ +19.19%▲ +15.62%$1.54 (−102.37%)
Showing 8 of 8

US Market Status

Market Closed — Opens in 7h 5m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access